Printer Friendly
The Free Library
14,560,361 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Veridien Makes Strategic Investment in Anti-Infectives/Drug Development Company.


Business Editors

ST PETERSBURG, Fla.--(BUSINESS WIRE)--Feb. 24, 2004

Veridien Corporation (OTCBB OTCBB

See OTC Bulletin Board (OTCBB).
:VRDE VRDE Vehicle Research and Development Establishment (India) ):

-- Highlights

-- Investment creates new product pipeline synergistic to

patented products now being marketed by Veridien and its

strategic distribution team

-- Anti-Infectives/Drug Development Company specializes in

development of Anti-Infective products which kill and retard

the regrowth Re`growth´   

n. 1. The act of regrowing; a second or new growth.
The regrowth of limbs which had been cut off.
- A. B. Buckley.
 of infective micro-organisms

-- New Anti-Infectives are expected to last up to days, months,

or years on treated surfaces

Veridien Corporation (OTCBB:VRDE) has made an initial strategic and equity investment in a private Anti-Infectives/Drug Development Company (ADDC).

Veridien's focus is on anti-infectives - quickly killing bacteria, mold, mildew and viruses - through its Patented Viraguard(R) product line of proprietary alcohol based liquid and towelette tow·el·ette  
n.
A small, usually moistened piece of paper or cloth used for cleansing.
 antiseptics and disinfectants. ADDC is developing complementary technologies of safe, potent, long lasting products that are expected to not only kill but retard the regrowth of infective microbials for days, weeks, months and possibly even years. This organization intends to focus its technology on the development of unique anti-microbials (bacteria, mold, yeast) and anti-infectives which are expected to feed the Veridien product pipeline and growing distribution channels. This management team has begun working with Veridien on its development projects and immediate marketing opportunities. Necessary regulatory approvals will be pursued by the joint highly qualified professional team.

Dr. Jerry A. Moore, PhD (Biology), JD (Environmental Law), Chairman of Veridien's Scientific Advisory Board said, "We live in a highly infected world. We are vulnerable to infectious diseases that are being spread worldwide. Viraguard(R) Infection Control Products enhance protection against and helps minimize the spread of many of these diseases. With the development of new anti-infective technologies, Veridien has a significant opportunity to broaden its portfolio and add biostatic products that prevent growth of infective microbials to our current line of patented biocidal bi·o·cid·al
adj.
Of or relating to an agent that is destructive to living organisms.


biocidal (bī´ōsī´d
 Infection Control Products."

Dr. Moore served for more than 25 years with the EPA EPA eicosapentaenoic acid.

EPA
abbr.
eicosapentaenoic acid


EPA,
n.pr See acid, eicosapentaenoic.

EPA,
n.
, with 17 years in the Pesticide Programs Office in Washington, DC. He served in the Office of Research and Development in the EPA where he acted as liaison with other federal agencies. Dr. Moore has broad expertise in the field of pesticide science and governmental regulation of products used for environmental disinfection disinfection,
n the process of destroying pathogenic organisms or rendering them inert.

disinfection, full oral cavity,
n a procedure used to reduce active periodontal disease, usually completed within a certain short time frame.
.

About Veridien:

Veridien Corporation is a Health Care and Anti-Infectives Company focusing on Infection Control and other Healthy Lifestyle products. Veridien has developed patented and unique products including surface disinfectants, antiseptic hand cleansers, instrument presoak pre·soak  
tr.v. pre·soaked, pre·soak·ing, pre·soaks
To soak (laundry) before washing.

n.
1. The act or an instance of presoaking.

2. A liquid preparation in which laundry is presoaked.
, and sun protectant protectant /pro·tec·tant/ (pro-tek´tant) protective.

protectant, protective

1. affording defense or immunity.

2. an agent affording defense against harmful influence.
 products. The flagship product, Viraguard(R) Hospital Disinfectant/Cleaner and Instrument Presoak is a skin friendly, patented, U.S.- EPA and Health Canada registered, surface disinfectant. Viraguard(R) Antiseptic Hand Gel, Viraguard(R) Antiseptic Hand Spray and Viraguard(R) Antiseptic Hand Wipes are U.S.- FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 and Health Canada drug listed products utilizing Veridien's patented Virahol(R) formulation.

Look for Veridien at http://www.veridien.com

Special Note: Forward-looking statements in this press release are made pursuant to the "safe-harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, market acceptance of, and demand for, the Company's products, manufacturing, development and distributor issues, product pricing, competition, funding availability, technological changes and other risks not identified herein. The Company disclaims any intent or obligation to update any forward-looking statements.

"HEALTHY LIVING IS AN ADVENTURE - LET VERIDIEN GUIDE YOU"
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Feb 24, 2004
Words:551
Previous Article:MAPICS Delivers The Latest Release Of eProcurement And Portal: The Next Generation Of Web Services And Collaboration.
Next Article:Sterling Commerce Recognized as the Leader Among Data Synchronization Providers.
Topics:



Related Articles
Veridien To Increase Product Lines and R&D Through Stake in Anti-Infectives/Drug Development Company.
Veridien Corporation Posts Record Quarterly Earnings.
Veridien Corporation Increases Investment in Anti-Infective/Drug Development Company - Mycosol, Inc.; Secures Rights to Acquire Majority Ownership.
Seasoned Health Care Executives Supplement Veridien Management Team; to Assist in Driving Planned Growth.
AMRAD TO DEMERGE ANTI-INFECTIVES BUSINESS.
Veridien Profitable for Second Consecutive Quarter; Third Quarter Revenues Projected to Be Approximately $700,000.
Veridien And Partner Target Multi-Billion Dollar ``Mold'' Opportunity.
Veridien Third Quarter Revenues Increase by 69% over Same Period Last Year.
Veridien's 2004 Financial Results Reflect Improved Operating Performance.
AVEXA/CSIRO COLLABORATE ON TREATMENTS FOR INFECTIOUS DISEASES.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles